Fumiyoshi Morikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Fumiyoshi Morikawa has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Hiroshige Fujishiro
Department of Psychiatry Nagoya University Graduate School of Medicine Nagoya Aichi Japan
2 shared publications Kazuki Tabata
Department of Psychiatry Asahikawa Keisenkai Hospital Asahikawa Japan
2 shared publicationsShota Fukuya
Department of Psychiatry Asahikawa Keisenkai Hospital Asahikawa Japan
2 shared publicationsTomonori Murayama
Department of Psychiatry Asahikawa Keisenkai Hospital Asahikawa Japan
2 shared publications- Akihiko Kitamura
Research Team for Social Participation and Community Health, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan
1 shared publication - Chika Nishimura
Kurumi Clinic, Tokyo 156-0041, Japan
1 shared publication
Latest Publications
- Open Access
- 22 April 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 108, 104510
Electroconvulsive therapy for dementia with Lewy bodies: A systematic review and Japanese multicenter survey
- 22 April 2025
- Published by Elsevier in Asian Journal of Psychiatry
- Vol. 108, 104510
Open AccessElectroconvulsive therapy for dementia with Lewy bodies: A systematic review and Japanese multicenter survey
- 28 November 2024
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (12) , e70020
Evaluating Electroconvulsive Therapy for Dementia With Lewy Bodies, Including the Prodromal Stage: A Retrospective Study on Safety and Efficacy
Objectives: Managing symptoms, notably psychiatric symptoms, in dementia with Lewy bodies (DLB) is complex, affecting both patients and caregivers. People with DLB often react poorly to antipsychotics, limiting treatment options. Although electroconvulsive therapy (ECT)'s potential for DLB is acknowledged, evidence is scarce owing to limited studies. This study investigated ECT's effectiveness and safety for DLB and prodromal DLB with antecedent psychiatric symptoms.Methods: This retrospective study investigated people with DLB (N = 12) and mild cognitive impairment (MCI) with LB (N = 13), a prodromal form of DLB, who underwent ECT for psychiatric symptoms and had abnormal findings confirmed using dopamine transporter single‐photon emission computed tomography and 123I‐metaiodobenzylguanidine myocardial scintigraphy. We reviewed these patients' medical records and determined the severity of psychotic symptoms before and 1 week after the final ECT session with the Clinical Global Impressions Severity Scale (CGI‐S). Improvement in psychotic symptoms was evaluated approximately 1 week after the final ECT session using the CGI Improvement Scale (CGI‐I). Additionally, we assessed cognitive function and dementia severity before and after ECT, as well as any adverse events caused by ECT.Results: ECT significantly improved psychiatric symptoms, as assessed using the CGI‐S, with CGI‐I reports in the order of 60% “very much improved,” 20% “much improved,” 16% “minimally improved,” and 4% “no change.” Parkinsonism improved (Hoehn and Yahr: 1.76 ± 1.2 before vs. 1.04 ± 0.7 after, p < 0.001) as did dementia severity (Clinical Dementia Rating, p = 0.037). Adverse events included delirium in 24% of patients and amnesia in 4% of patients. ECT did not worsen cognitive function.Conclusions: ECT for DLB and MCI with LB with antecedent psychiatric symptoms appears safe and effective in managing psychiatric symptoms and Parkinsonism. Further large‐scale multicenter studies are warranted to conclusively establish its effectiveness and safety.
- 28 November 2024
- Published by Wiley in International Journal of Geriatric Psychiatry
- Vol. 39 (12) , e70020
Evaluating Electroconvulsive Therapy for Dementia With Lewy Bodies, Including the Prodromal Stage: A Retrospective Study on Safety and Efficacy
Objectives: Managing symptoms, notably psychiatric symptoms, in dementia with Lewy bodies (DLB) is complex, affecting both patients and caregivers. People with DLB often react poorly to antipsychotics, limiting treatment options. Although electroconvulsive therapy (ECT)'s potential for DLB is acknowledged, evidence is scarce owing to limited studies. This study investigated ECT's effectiveness and safety for DLB and prodromal DLB with antecedent psychiatric symptoms.Methods: This retrospective study investigated people with DLB (N = 12) and mild cognitive impairment (MCI) with LB (N = 13), a prodromal form of DLB, who underwent ECT for psychiatric symptoms and had abnormal findings confirmed using dopamine transporter single‐photon emission computed tomography and 123I‐metaiodobenzylguanidine myocardial scintigraphy. We reviewed these patients' medical records and determined the severity of psychotic symptoms before and 1 week after the final ECT session with the Clinical Global Impressions Severity Scale (CGI‐S). Improvement in psychotic symptoms was evaluated approximately 1 week after the final ECT session using the CGI Improvement Scale (CGI‐I). Additionally, we assessed cognitive function and dementia severity before and after ECT, as well as any adverse events caused by ECT.Results: ECT significantly improved psychiatric symptoms, as assessed using the CGI‐S, with CGI‐I reports in the order of 60% “very much improved,” 20% “much improved,” 16% “minimally improved,” and 4% “no change.” Parkinsonism improved (Hoehn and Yahr: 1.76 ± 1.2 before vs. 1.04 ± 0.7 after, p < 0.001) as did dementia severity (Clinical Dementia Rating, p = 0.037). Adverse events included delirium in 24% of patients and amnesia in 4% of patients. ECT did not worsen cognitive function.Conclusions: ECT for DLB and MCI with LB with antecedent psychiatric symptoms appears safe and effective in managing psychiatric symptoms and Parkinsonism. Further large‐scale multicenter studies are warranted to conclusively establish its effectiveness and safety.
- 21 February 2024
- Published by Wiley in Psychogeriatrics
- Vol. 24 (3) , 725-726
Difficulties in diagnosing phenoconversion to dementia in psychiatric‐onset prodromal dementia with Lewy bodies
- 21 February 2024
- Published by Wiley in Psychogeriatrics
- Vol. 24 (3) , 725-726
Difficulties in diagnosing phenoconversion to dementia in psychiatric‐onset prodromal dementia with Lewy bodies
- Open Access
Development of a Novel Nutrition-Related Multivariate Biomarker for Mild Cognitive Impairment Based on the Plasma Free Amino Acid Profile
Nutritional epidemiology has shown the importance of protein intake for maintaining brain function in the elderly population. Mild cognitive impairment (MCI) may be associated with malnutrition, especially protein intake. We explored blood-based biomarkers linking protein nutritional status with MCI in a multicenter study. In total, 219 individuals with MCI (79.5 ± 5.7 year) from 10 institutions and 220 individuals who were cognitively normal (CN, 76.3 ± 6.6 year) in four different cities in Japan were recruited. They were divided into the training (120 MCI and 120 CN) and validation (99 MCI and 100 CN) groups. A model involving concentrations of PFAAs and albumin to discriminate MCI from CN individuals was constructed by multivariate logistic regression analysis in the training dataset, and the performance was evaluated in the validation dataset. The concentrations of some essential amino acids and albumin were significantly lower in MCI group than CN group. An index incorporating albumin and PFAA discriminated MCI from CN participants with the AUC of 0.705 (95% CI: 0.632–0.778), and the sensitivities at specificities of 90% and 60% were 25.3% and 76.8%, respectively. No significant association with BMI or APOE status was observed. This cross-sectional study suggests that the biomarker changes in MCI group may be associated with protein nutrition.
Open AccessDevelopment of a Novel Nutrition-Related Multivariate Biomarker for Mild Cognitive Impairment Based on the Plasma Free Amino Acid Profile
Nutritional epidemiology has shown the importance of protein intake for maintaining brain function in the elderly population. Mild cognitive impairment (MCI) may be associated with malnutrition, especially protein intake. We explored blood-based biomarkers linking protein nutritional status with MCI in a multicenter study. In total, 219 individuals with MCI (79.5 ± 5.7 year) from 10 institutions and 220 individuals who were cognitively normal (CN, 76.3 ± 6.6 year) in four different cities in Japan were recruited. They were divided into the training (120 MCI and 120 CN) and validation (99 MCI and 100 CN) groups. A model involving concentrations of PFAAs and albumin to discriminate MCI from CN individuals was constructed by multivariate logistic regression analysis in the training dataset, and the performance was evaluated in the validation dataset. The concentrations of some essential amino acids and albumin were significantly lower in MCI group than CN group. An index incorporating albumin and PFAA discriminated MCI from CN participants with the AUC of 0.705 (95% CI: 0.632–0.778), and the sensitivities at specificities of 90% and 60% were 25.3% and 76.8%, respectively. No significant association with BMI or APOE status was observed. This cross-sectional study suggests that the biomarker changes in MCI group may be associated with protein nutrition.